Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Ms. Annie  Ganot

Co-Founder & Head of Patient Advocacy

Mr. Ian F. Smith A.C.A., C.P.A.

Executive Chair

Mr. David Tyronne Howton Jr., J.D.

Chief Operating Officer & Secretary

Mr. Paul  Herzich

Chief Technology Officer

Mr. Kevin  Tan C.F.A.

Chief Financial Officer & Treasurer

Dr. Andrey Juan Zarur Ph.D.

Co-Founder

Mr. Gilad David Hayeem

Mr. Alexander G. Cumbo

President, Chief Executive Officer & Director

Mr. Ilan  Ganot

Co-founder, Strategic Advisor to the Chief Executive Officer & Director

Mr. Stephen J. Di Palma M.B.A.

Treasurer & Principal Accounting Officer

Biotechnologia

Solid Biosciences Inc.

Solid Biosciences Inc. Struktura zarządzania

Informacje o kierownictwie